| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |

Department of Physiology, University of British Columbia Vancouver, British Columbia, Canada V6T 1W5
Abstract
Gastric inhibitory polypeptide (GIP) produced an increase in immunoreactive insulin (IRI) and immunoreactive glucagon (IRG) release from the isolated perfused rat pancreas. The magnitude of both effects was shown to be dependent on the prevailing glucose concentration. GIP stimulated IRG release at glucose concentrations less than 5.5 mM and IRI release at glucose levels greater than 5.5 mM. Arginine-stimulated IRG secretion in the presence of low glucose (2.7 mM) was potentiated by GIP. In contrast, GIP augmented arginine-stimulated insulin release only in the presence of arginine concentrations of <20 mM, producing no further increase over a maximal arginine stimulus. The glucagonotropic effect of GIP in the presence of arginine was found to be suppressed by glucose, with the opposite effect observed with insulin release. It was concluded that the endocrine pancreatic action of GIP depends to a great degree on existing levels of modulating nutrients in the blood.
Footnotes
* This work was supported by research grants from the MRC of Canada.
To whom all correspondence and requests for reprints should be addressed.
Received November 21, 1977.
This article has been cited by other articles:
![]() |
C. W. Chia, O. D. Carlson, W. Kim, Y.-K. Shin, C. P. Charles, H. S. Kim, D. L. Melvin, and J. M. Egan Exogenous Glucose-Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes Diabetes, June 1, 2009; 58(6): 1342 - 1349. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Kim and J. M. Egan The Role of Incretins in Glucose Homeostasis and Diabetes Treatment Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Vollmer, J. J. Holst, B. Baller, M. Ellrichmann, M. A. Nauck, W. E. Schmidt, and J. J. Meier Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance Diabetes, March 1, 2008; 57(3): 678 - 687. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Miki, K. Minami, H. Shinozaki, K. Matsumura, A. Saraya, H. Ikeda, Y. Yamada, J. J. Holst, and S. Seino Distinct Effects of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 on Insulin Secretion and Gut Motility Diabetes, April 1, 2005; 54(4): 1056 - 1063. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Deacon, P. Danielsen, L. Klarskov, M. Olesen, and J. J. Holst Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs Diabetes, July 1, 2001; 50(7): 1588 - 1597. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Sherwood, S. L. Krueckl, and J. E. McRory The Origin and Function of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)/Glucagon Superfamily Endocr. Rev., December 1, 2000; 21(6): 619 - 670. [Abstract] [Full Text] |
||||
![]() |
J. T. Lewis, B. Dayanandan, J. F. Habener, and T. J. Kieffer Glucose-Dependent Insulinotropic Polypeptide Confers Early Phase Insulin Release to Oral Glucose in Rats: Demonstration by a Receptor Antagonist Endocrinology, October 1, 2000; 141(10): 3710 - 3716. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Ehses, S. S. T. Lee, R. A. Pederson, and C. H. S. McIntosh A New Pathway for Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor Signaling. EVIDENCE FOR THE INVOLVEMENT OF PHOSPHOLIPASE A2 IN GIP-STIMULATED INSULIN SECRETION J. Biol. Chem., June 22, 2001; 276(26): 23667 - 23673. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |